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Objective: Asenapine is approved for acute manic and mixed states in bipolar disorder. The 
objective is to review the efficacy of asenapine in bipolar disorder, with a particular focus on 
acceptability and adherence to treatment.
Methods: Five clinical trials were conducted in bipolar disorder manic or mixed states: two 
3-week trials (n = 976) comparing asenapine to placebo, a 9-week extension (n = 504), and a 
40-week extension (n = 107). One trial was conducted comparing asenapine to placebo (n = 326) 
as adjunctive therapy for subjects with an incomplete response to lithium or valproate. All trials 
were conducted in the USA and internationally.
Results: Asenapine was found to be efficacious for manic and mixed states in bipolar disorder 
compared with placebo control, and compares equally well to olanzapine on efficacy measures 
after 3 weeks of treatment. Asenapine was not found to be efficacious for depression symptoms. 
Common asenapine side effects in the 40-week extension trial were sedation, insomnia, and 
dizziness, and 31% reported clinically significant weight gain, compared with 55% reporting 
clinically significant weight gain with olanzapine. Additionally, 18% had clinically significant 
changes in fasting blood glucose levels compared to 22% of those on olanzapine. In terms of 
patient acceptability, one concern may be sublingual administration requiring no liquids or food 
for 10 minutes after dosing and a twice-daily regimen. Suggestions about addressing barriers 
to adherence and acceptability are provided.
Conclusion: Asenapine is a promising new medication in bipolar disorder. Asenapine in the 
long-term has a more favorable weight gain profile compared to olanzapine. No benefit was 
seen for depression symptoms, a major patient-reported concern. Some side effects do not remit 
after the short-term trials in at least 10% of patients.
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Introduction
Adherence to medication in bipolar disorder
Treatment guidelines in bipolar disorder recommend ongoing pharmacological treat-
ment for individuals who have had more than one mood episode.1,2 As bipolar disorder 
is a chronic illness, it is imperative that medication to treat its symptoms and prevent 
relapse are acceptable to patients not only during acute phases, but also during the 
long-term course of the illness.
Medication adherence estimates in bipolar disorder vary across studies based on 
definitions of adherence, length of follow up, and the population studied,   averaging 
30%–50%.3–7 As with most chronic illnesses, adherence to medication regimens is 
a major focus in clinical and research settings.3,8   Nonadherence to medications can Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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result in severe symptoms and increased mood episodes, 
increased psychiatric hospitalizations, and suicidality.3,8,9 
Most of the bipolar disorder adherence literature has exam-
ined attitudes toward lithium, a primary mood-stabilizing 
medication intervention,5,7,10 with valproic acid and second 
generation antipsychotics also providing mood-stabilizing 
effects. Doctors and patients must make collaborative deci-
sions about the benefit to risk ratios of potential medications 
to treat bipolar disorder.11,12
Velligan et al provide a comprehensive review of fac-
tors contributing to nonadherence in bipolar disorder.8 
Demographic factors, particularly younger age or being of 
ethnic minority status, deficits in cognitive functioning, and 
logistical problems interfering with medication routines (eg, 
housing, financial, chaotic social environment) decrease 
adherence. Poor insight into one’s illness or into the need 
for medication, or negative attitudes toward medications 
can negatively impact adherence. Co-occurring substance 
abuse, a poor quality therapeutic relationship, and mini-
mal social support are other factors.8 One concern specific 
to bipolar disorder is that patients with bipolar disorder 
might view antipsychotics as more stigmatizing than mood 
stabilizers.13 Medication helpful in treating depression can 
positively impact adherence.14 Persons with bipolar disorder 
note that the top two areas of concern in their patient care are 
medications that provide less risk of weight gain and better 
treatment for depression.15 As for reasons for nonadherence 
to antipsychotics in particular, medication side effects can 
be a major factor.
Adherence in antipsychotic medication
Side effects most often associated with antipsychotic medi-
cations include somnolence, sedation, insomnia, dizziness, 
headaches, gastrointestinal symptoms, sexual dysfunction, 
and extrapyramidal symptoms (EPS). The metabolic and 
weight gain side effects associated with antipsychotics 
may be the biggest contributors to nonadherence due to 
side effects.16 That is, increased adiposity, increased blood 
pressure, abnormal cholesterol, and triglyceride levels and 
insulin resistance, which can lead to increased rates of dia-
betes and heart disease.16 In a recent report, the medication 
side effect reported most often among 1155 persons with 
schizophrenia and 1300 persons with bipolar disorder was 
weight gain.15
Antipsychotics are now prescribed in approximately 
45% of patients in the medication management of bipo-
lar disorder.9 Six antipsychotic medications have been 
  FDA-approved to treat various phases of bipolar disorder, 
with asenapine (Saphris®, Merck and Co, IncKenilworth, NJ) 
being the most recent FDA approval in August 2009. In this 
paper, we describe the efficacy, tolerability, and side effect 
profile of asenapine, with a particular focus on tolerability 
and long-term side effects. We will compare these data with 
side effect profiles of other FDA approved antipsychotics 
in bipolar disorder. We will provide clinical suggestions for 
when asenapine should be considered for treatment of manic 
or mixed episodes.
Asenapine
Overview
Asenapine is an atypical antipsychotic indicated for the 
treatment of schizophrenia and for the acute treatment 
of manic or mixed episodes, with or without psychotic 
features, associated with bipolar disorder. Asenapine is 
approved as monotherapy and as adjunctive therapy. The 
initial recommended dose of asenapine monotherapy for 
bipolar disorder is 20 mg total daily dose (10 mg sublin-
gually twice daily), which is also the recommended target 
dose. For adjunctive therapy, the recommended dose is 
10–20 mg. The safety of total daily doses above 20 mg 
has not been evaluated in clinical trials. Ninety percent of 
bipolar patients in registration trials required 10 mg twice 
daily for a clinical response.
Pharmacology/pharmacokinetics
The exact mechanism by which asenapine reduces manic 
symptoms associated with bipolar disorder is unknown. 
Asenapine has high affinity for serotonin receptors (5-HT1a, 
5-HT1b, 5-HT2a, 5-HT2b, 5-HT2c, 5-HT5, 5-HT6, and 
5-HT7), dopamine receptors (D1, D2, D3, and D4), Alpha 
1 and 2 receptors, and histamine (H1) receptors. It also has 
moderate affinity for histamine (H2) receptors. Asenapine 
acts as an antagonist at all these receptors. Unlike some 
other antipsychotics (eg, olanzapine) asenapine has no 
appreciable binding to muscarinic receptors. The mean half-
life of asenapine is 24 hours and steady state concentrations 
are achieved in 3 days with multiple dosing. Absorption 
pharmacokinetics are very important with asenapine as the 
absolute bioavailability of asenapine taken sublingually is 
approximately 35%, but if swallowed the bioavailability is 
less than 2%.17 Patients must be properly counseled on the 
importance of taking asenapine sublingually with no drink-
ing or eating 10 minutes after administration. Asenapine is 
metabolized via direct glucuronidation by UGT1A4 and 
oxidative metabolism by cytochrome P450 isoenzymes 
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Efficacy
Efficacy studies of asenapine have included two 3-week 
  trials, a 9-week extension trial, a 40-week extension trial, 
and a 52-week adjunctive therapy trial.18–22 The 3-week trials 
resulted in FDA approval (ARES 7501004, ARES 7501005), 
involved 976 subjects across 62 centers internationally, and 
had similar research designs. Subjects were randomized to 
receive flexible dosing asenapine 5–10 mg bid (n = 379), 
olanzapine 2–20 mg/d (n = 395), or placebo (n = 202). 
Subjects had a diagnosis of bipolar I disorder with a current 
manic or mixed episode and a Young Mania Rating Scale 
(YMRS)23 score $ 20. Excluded subjects included those 
with current substance abuse, “clinically significant medical 
conditions or laboratory abnormalities,” and rapid cycling 
bipolar disorder.
The studies were single blind placebo run-in for 7 days, 
where all psychiatric medications were discontinued in an 
inpatient setting except for benzodiazepines, nonbenzosedative 
hypnotics, and medications used to treat EPS. Benzodiazepines 
and sleep enhancers were used for agitation or insomnia and 
were discontinued by day 7, and every effort was made to 
discontinue medication used to treat EPS. Subjects were 
then randomized to asenapine, olanzapine, or placebo for 
21 days. Subjects remained inpatients for 7 or more days and 
the trial then continued on an outpatient basis if clinically 
indicated. The mean daily dose of asenapine across trials 
was 18.3 ± 3 mg. Both trials showed a significant reduction 
in YMRS scores for asenapine compared to baseline scores 
at day 21; average change across the two studies was −11 for 
asenapine, −14 for olanzapine, and −7 for placebo. The effect 
size of change for olanzapine was significantly greater than for 
asenapine in study 7501004.19 For secondary outcomes, the 
Clinical Global Impression for Bipolar Disorder mania severity 
score24 (CGI-BP) was similarly reduced. The Montgomery–
Asberg Depression Rating Scale25 was significantly reduced 
only for olanzapine compared with placebo at day 21 for 
both trials. Trial 7501005 reported significant differences 
from placebo in response ($50% reduction in YMRS) and 
remission (YMRS # 12), while there were no differences in 
7501004 (see Table 2).   Olanzapine differed from placebo on 
secondary outcomes for both trials.
When subjects completed the 3-week trial they were 
eligible to participate in a 9-week blinded extension study.22 
Subjects remained on the same nonplacebo treatment as 
the 3-week trial and the placebo group was assigned to 
asenapine. Inclusion and exclusion criteria were similar 
to the 3-week trial criteria. Five hundred and four subjects 
participated (placebo/asenapine = 94, asenapine = 181, and 
olanzapine = 229). Each group continued to improve on 
manic symptoms. At study end on day 84 (including the 
3-week-trial days), both the asenapine and olanzapine groups 
had significant reductions in YMRS (−24.4 asenapine and 
−23.9 olanzapine) with no significant differences between 
asenapine and olanzapine. There were no significant 
differences between the rates of response ($50% reduction 
in YMRS, 90%, 92%) and remission (YMRS # 12, 88%, 
91%) for asenapine and olanzapine, respectively. Less than 
2% of subjects in any group showed significant worsening 
of manic symptoms. With secondary outcomes, at day 84 
there was no significant difference between asenapine and 
olanzapine for MADRS (change scores: asenapine = −2.6, 
olanzapine = −2.4) and CGI-BP scores (change score: 
asenapine = −3.6, olanzapine = −2.4). Using overall CGI-BP 
illness scores, 3% of the asenapine and 7% of the olanzapine 
group had higher (worse) CGI-BP scores; not a significant 
difference.
If subjects completed the 9-week extension they 
had the option of enrolling in a double-blind 40-week 
extension study (placebo/asenapine = 32, asenapine = 79, 
and olanzapine = 107), with the primary aim of assessing 
safety and tolerability (discussed in further detail below).21 
At study end there was no statistical difference between 
asenapine and olanzapine on changes in the YMRS from 
baseline (asenapine = −29, olanzapine = −28), the CGI-BP 
(asenapine = −3.6, olanzapine = −3.2), or in MADRS scores 
(asenapine = −4.8, olanzapine = −4.4). At study end, the 
rates of YMRS response and remission for asenapine (95%) 
and olanzapine (98%) were not statistically different. There 
was no statistical difference in worsening of mania ($25% 
increase in YMRS from baseline) between asenapine (2.6%) 
and olanzapine (1.9%).
The fifth pharmaceutical trial was 12-week placebo 
controlled and conducted at 74 international sites.20 
Asenapine was used as adjunctive therapy when subjects 
had an incomplete response to a mood stabilizer (lithium 
or valproate) in  bipolar I disorder manic or mixed episodes 
(asenapine = 159, placebo = 167). At week 3, the asenapine-
treated group showed a significant improvement on the 
YMRS compared to placebo,17 with no improvements 
seen in depression (MADRS). The study was extended for 
40 weeks, and at 52 weeks no differences in change from 
baseline on the YMRS or MADRS compared to placebo 
were observed.20
Only one asenapine 3-week trial has reported on efficacy 
specifically by episode type (manic or mixed).18 At day 2, 
asenapine was significantly better than placebo on YMRS Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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scores. No significant differences, although a trend, were 
observed for mixed episodes at day 21.
Patients not included in clinical trials include those under 
18 or over 65 years old, those with bipolar II disorder, bipolar 
not otherwise specified, or those with rapid cycling and comor-
bid substance abuse. There may be differences in primary or 
secondary outcomes by ethnicity/race, as has been reported in 
other clinical trials.26
Overall the efficacy data on asenapine suggests that 
considering manic and mixed episodes together, there are 
significant decreases in manic symptoms after 21 days; 
however, olanzapine may have a more rapid effect on manic 
symptoms prior to 21 days. There was less benefit seen with 
depressive symptoms with asenapine than for olanzapine at 
day 21 for both 3-week trials, while in the long term there were 
no differences in depression symptoms between medications. 
In the long term, asenapine performed equally well to olan-
zapine across primary and secondary measures when used as 
monotherapy; however, as adjunctive therapy there may be no 
long-term benefit of asenapine on manic symptoms.
Safety and tolerability
The most common adverse reactions reported by patients 
($5% and at least twice the rate as placebo) in the mono-
therapy 3-week clinical trials were somnolence, dizziness, 
EPS other than akathisia and weight increase.18,19 Adverse 
effects from discontinuation of asenapine (at least 1% and 
twice the rate of placebo) are anxiety (1.1%) and oral hypo-
esthesia (1.1%) compared to placebo (0%).18,19
Data from the 9-week extension show similar adverse 
effects: sedation, dizziness, and insomnia were the most com-
monly reported.22 Rates of EPS were similar in patients’ first 
receiving placebo then asenapine (10%), asenapine (15%), 
and olanzapine (13%); akathisia, tremor, and parkinsonism 
were the most prevalent.
In the 40-week extension the common adverse effects 
($10% in any treatment group) in the placebo/asenapine group 
were insomnia, headache, somnolence, nausea, parkinsonism, 
tremor, and constipation.21 Insomnia, sedation, depression, 
headache, somnolence, weight increase, dizziness, nausea, 
and akathisia were most common for the asenapine only group 
throughout the 3-, 9-, and 40-week   trials.21 Table 1 provides 
a summary of adverse events across the clinical trials and 
includes a comparison to olanzapine for the 40-week trial.
Metabolic outcomes
Metabolic side effects are of great concern with atypical 
antipsychotics. The 3-week clinical trials reported a mean 
increase in fasting blood glucose (n = 379) similar to placebo 
(n = 203) at 0.6 mg/dL. The proportions of bipolar patients 
with fasting glucose elevations $126 mg/dL (at 3 weeks) was 
4.9% in the asenapine-treated group versus 2.2% in placebo 
treated patients. The effect of asenapine on total cholesterol 
and triglycerides was a 1.1 mg/dL increase in total cholesterol 
versus a 1.5 mg/dL decrease in the placebo group and a 3.5 mg/
dL decrease in triglycerides versus a 17.9 mg/dL decrease in 
triglycerides in the placebo group. The proportion of patients 
with total cholesterol elevations $240 mg/dL (at 3-week 
endpoint) was 8.7% for asenapine-treated patients versus 8.6% 
for placebo-treated patients. The proportion of patients with 
elevations in triglycerides $200 mg/dL (at 3-week endpoint) 
was 15.2% for asenapine versus 11.4% for placebo.
In the 9-week extension study, patients treated with 
asenapine (n = 181) had changes from baseline values of 
−7.1 ± 84.1 mg/dL in triglycerides, 2.2 ± 21.6 mg/dL in 
fasting glucose, −0.8 ± 34.4 mg/dL in total cholesterol, 
−1.5 ± 26.3 mg/dL in low-density lipoprotein (LDL) choles-
terol, and 1.5 ± 10.0 mg/dL in high-density lipoprotein (HDL) 
cholesterol. Placebo/Asenapine-treated patients (n = 94) 
had changes from baseline values of −21.2 ± 128.3 mg/
dL in triglycerides, 2.0 ± 18.2 mg/dL in fasting glucose, 
0.8 ± 31.3 mg/dL in total cholesterol, 1.9 ± 27.8 mg/dL in 
LDL cholesterol, 1.2 ± 9.3 mg/dL in HDL cholesterol; and 
olanzapine treated patients (n = 229) had changes from baseline 
values of 30.1 ± 115.9 mg/dL in   triglycerides, 3.1 ± 18.4 mg/dL 
in fasting glucose, 12.4 ± 34.4 mg/dL in total cholesterol, 
10.0 ± 30.5 mg/dL in LDL cholesterol, −1.2 ± 11.2 mg/dL in 
HDL cholesterol.
By the end of the 40-week extension, patients treated 
with asenapine (n = 79) had changes from baseline values of 
6.02 mg/dL in triglycerides, −0.63 mg/dL in fasting glucose, 
−4.56 mg/dL in total cholesterol, −2.97 mg/dL in LDL 
cholesterol, and −1.08 mg/dL in HDL cholesterol. Placebo/
Asenapine-treated patients (n = 32) had changes from baseline 
values of −44.6 mg/dL in triglycerides, 2.47 mg/dL in fasting 
glucose, 7.61 mg/dL in total cholesterol, 8.69 mg/dL in LDL 
cholesterol, and 3.55 mg/dL in HDL cholesterol. Olanzapine-
treated patients (n = 107) had changes from baseline values of 
32.04 mg/dL in triglycerides, 7.12 mg/dL in fasting glucose, 
16.99 mg/dL in total cholesterol, 13.44 mg/dL in LDL 
cholesterol, and −2.39 mg/dL in HDL cholesterol.
Weight gain in the 3-week monotherapy registration trials 
was seen in 5% of asenapine-treated patients versus ,1% 
for placebo. Weight gain during the 9-week extension trial 
showed clinically significant weight gain ($7% increase from 
baseline) in 19% of asenapine-, 10% placebo/asenapine-, and Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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Table 1 Side effect profiles across four clinical trials of asenapine
Side effects 3 weeksb  
(n = 379) (%)
4–12 weeksc  
(n = 181) (%)
13–52 weeksc  
(n = 79) (%)
Olanzapine  
13–52 weeks   
(n = 107) (%)
Sedation 14 14 17 16
Somnolence 14 12 14 16
insomnia – 13 20 12
Headache – 21 14 14
Dizziness 11 24 13 6
Nausea – 8 13 13
Constipation – 10 6 6
Dry mouth 4 7 – –
vomiting 5 – – –
Appetite increase 4 – – –
Depression – – 15 8
Metabolica
  weight gain 7 19 31 55
    Blood glucose levels  
(elevated or decreased levels)
12 12 18 22
  Triglycerides 0 – – –
  weight loss 2 7 – –
  Prolactin 0 3 3 3
ePS
  Tremor – – 8 5
  Akathisia 4 – 11 10
  Parkinsonism 2 – 8 4
  Dystonia 4 – 4 1
  Bradykinesia 2 – 4 2
  Dyskenisia 1 – 1 0
  Gait disturbance 0 – 3 0
  Masked facies – – 1 0
  Tardive dyskinesia – – 3 0
Notes: aPercentages denote clinically significant changes; baverage of 3-week trial data; cpercentages do not include the placebo/asenapine group that started asenapine after 
a 3-week delay.
Abbreviation: ePS, extrapyramidal symptoms.
31% olanzapine-treated patients.22 In the 40-week extension, 
clinically significant weight gain ($7% increase from 
baseline) occurred in 39.2% of asenapine-treated patients, 
21.9% placebo/asenapine, and 55.1% of olanzapine-treated 
patients. Eighteen percent of the subjects in the 40-week 
extension trial had clinically significant changes in fasting 
blood glucose levels.
Table 1 provides a summary of side effects and clinically 
significant metabolic outcomes across studies. In the long-
term asenapine users, many continue to have somnolence, 
sedation, insomnia, headaches, and other side effects includ-
ing EPS although these effects are similar to what is observed 
in olanzapine. Over time, asenapine has a more favorable pro-
file for weight gain than olanzapine. The laboratory findings 
Table 2 Summary of efficacy and discontinuation data for asenapine using last observation carried forward analyses
3-week trial  
(n = 185)  
7501004
3-week trial  
(n = 194)  
7501005
9 weeksc  
(n = 275)
40 weeksc  
(n = 112)
Efficacy Mean change from baseline ± standard deviation
  YMRS −11.5 ± 0.8a,b −10.8 + 0.8a −24.4 ± 8.7 −25.8 ± 10.3
  Clinical global impression for bipolar disorder −1.2 ± 0.10a,b −1.2 + 0.1a −2.8 ± 0.09 −3.2 ± 1.3
  Montgomery–Asberg depression rating scale −3.0 ± 0.4 −3.2 +0.5 −3.6 ± 0.69 −4.8 ± 6.5
Response ($50% improvement on YMRS) 78 (43%) 81 (42%)a 212 (77%) 110 (98%)d
Remission (#12 YMRS) 67 (36%) 78 (40%)a 206 (75%) 110 (98%)d
Dropout rates 61 (33%) 72 (37%) 113 (41%) 46 (41%)
Notes: aDiffers from placebo; bdiffers from olanzapine favoring olanzapine; cno placebo group; dresponse and remission rates were reported as one percentage.
Abbreviation: YMRS, Young mania rating scale.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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suggest that asenapine does not have profound effects, but 
weight gain, fasting glucose, and lipids should be monitored 
closely. It is also important to note that the more commonly 
reported range for fasting glucose is .110 mg/dL, the range 
cholesterol elevations is $200 mg/dL, and the range for 
elevated triglycerides is $150 mg/dL.27
Patient acceptability
Study dropout rates putatively take into account both efficacy 
and adverse effects and thus overall tolerability of a   medication. 
Ten percent of asenapine treated patients (n = 38/379) in the 
3-week trials discontinued treatment due to adverse events, 
compared to 6% on placebo (n = 12/203). In 3-week trial 
7501004, completion rates were as follows: 58% placebo, 
67% asenapine, and 79% olanzapine. For asenapine, adverse 
events and mania were the most frequent reasons for leaving 
the trial. Of serious adverse events, 9 of 12 were worsening 
of disease (placebo 5 of 7, olanzapine 3 of 8). Subjects were 
significantly more likely to complete the trial when taking 
olanzapine.19 In 3-week trial 7501005, completion rates were as 
follows: 62% placebo, 63% asenapine, and 80% olanzapine;18 
the completion rate was significantly higher with olanzapine. 
The most frequent reasons for discontinuation of asenapine 
were 8% lack of efficacy, 10% adverse events (mania was the 
most common adverse event), and 14% withdrew their consent. 
Mania as an adverse event was rated independently from lack 
of efficacy, so the subject could have had both reasons coded 
for dropout per clinician impression.
Over the 40-week trial, 40% of the placebo/asenapine sub-
jects completed the study, 65.8% of the asenapine subjects, 
and 63.6% of the olanzapine group.21 Discontinuation rates 
due to adverse events were highest in the placebo/asenapine 
group (n = 5, 15.6% of dropouts) but were comparable in 
the asenapine (n = 7, 8.9%) and olanzapine (n = 9, 8.4%) 
groups. Among all patients who received asenapine, the 
discontinuation rate due to adverse events was 11% while 
discontinuation due to lack of efficacy averaged 41% across 
patients taking asenapine.
Sexual dysfunction is a concern for individuals with 
bipolar disorder taking antipsychotic medications,28 and 
may be a hidden cause of nonadherence to antipsychotic 
medication.29 Noen of the trials reported sexual side effects. 
One patient acceptability concern with asenapine is the 
sublingual administration and the requirement of no food 
or water for 10 minutes after administration.30 Asenapine is 
dosed twice daily, which may be more challenging than once 
daily regimens. Some patients with cognitive difficulties such 
as memory or disorganization may have difficulties adhering 
to this regimen. Some individuals anecdotally report bad taste 
of the medication and/or oral hypoesthesia.
Metabolism
Asenapine has been found to be a weak inhibitor of 
  cytochrome P-450 2D6, so major drug interactions are not 
expected; but it should be used with caution with other agents 
that are metabolized by CYP 2D6 (eg, paroxetine, most 
tricyclic antidepressants, amoxapine, captopril, duloxetine, 
fluoxetine, fluvoxamine, haldol). Co-administration of a 
single 20-mg dose of paroxetine during treatment with 5 mg 
asenapine twice daily in 15 healthy male subjects resulted in 
an almost 2-fold increase in paroxetine exposure.17 Asenapine 
may enhance the inhibitory effects of paroxetine on its 
own metabolism. Also since asenapine is metabolized by 
CYP 1A2, caution should be used with co-administration 
with agents/conditions that induce CYP 1A2 (eg, smok-
ing, carbamazepine, or rifampin) or inhibit CYP 1A2 (eg, 
  fluvoxamine, ciprofloxacin, or ketoconazole).
Asenapine does not require any dosage adjust-
ment in renal impairment. In severe hepatic impairment 
(Child–Pugh C), asenapine is not recommended. Asenapine 
levels were 7-fold higher in patients with Child–Pugh C 
classified hepatic impairment versus patients with normal 
hepatic function.
Black box warning
As is the case for all antipsychotic medications prescribed 
to elderly individuals, there is a black box warning for 
asenapine. Elderly patients with dementia-related psychosis 
treated with antipsychotic drugs are at an increased risk of 
death, due to cerebrovascular adverse reactions including 
fatalities.
Discussion
Asenapine is a recently FDA-approved atypical antipsychotic 
which has shown benefits in treating manic and mixed states 
as monotherapy in bipolar disorder up to one year after 
initiation of treatment. In two 3-week trials, asenapine 
had a higher dropout rate than olanzapine, often due to 
continuing manic symptoms. After 3 weeks, asenapine per-
forms as well as olanzapine on primary efficacy outcomes. 
In a trial to assess the adjunctive effects of asenapine on 
manic and mixed states, there were short-term benefits on 
manic symptoms, but no additional benefits in the long-
term for asenapine versus placebo as adjunctive therapy.20 
Asenapine is FDA approved to treat manic and mixed 
episodes in bipolar disorder. However, asenapine may be Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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less effective for mixed states in the short-term. Only one 
asenapine 3-week trial reported by subgroup, and they noted 
significant improvements at day 2 compared to placebo, with 
the improvement not statistically significant compared to 
placebo by day 21. Additional subgroup analyses on mixed 
states would be beneficial.
Asenapine did not show improvement on depressive 
symptoms in the short term or long term. During the 
40-week extension period, 15% of subjects had worsen-
ing of depression symptoms while 8% of the olanzapine 
group had worsening symptoms. Thus, one of the primary 
interests of new pharmaceuticals from a patient’s perspec-
tive (ie, treating depressive symptoms)15 is not addressed 
by asenapine. Weight gain was the other patient-expressed 
concern. Greater weight gain in the olanzapine group 
emerged in the initial 3-week trials. In a year’s time, 31% 
of the asenapine group had clinically significant weight 
gain, as compared with 55% with olanzapine. Compared 
with olanzapine, asenapine has a more favorable weight 
gain side effect profile although both compounds have a 
significant impact on weight. Elevated fasting blood glucose 
levels were comparable in asenapine and olanzapine in the 
long-term trial. Monitoring of lab values and metabolic 
outcomes with asenapine is crucial.
Long-term side effects reported by at least 10% of 
the asenapine group are sedation, somnolence, insomnia, 
headache, dizziness, nausea, and akathisia. Tremor and 
parkinsonism were reported by 8% of subjects. None of 
the clinical trials reported the frequency or seriousness of 
sexual dysfunction while taking asenapine. Sexual dys-
function may be a hidden cause of nonadherence to antip-
sychotic medication28,29 as clinicians may underestimate 
the frequency of sexual side effects. Further attention to 
this topic in future trials is warranted. A consideration of 
these side effects in prescribing asenapine will be essential 
to adherence to the treatment regimen. Table 3 provides an 
overview of side effect profiles across medications used to 
treat bipolar disorder.
Other antipsychotics might have similar or more favor-
able weight gain profiles. In a 3-week trial, weight gain for 
risperidone (3.53 pounds) was significantly less than for 
olanzapine (5.42 pounds).31 In a 6-month trial of risperidone 
to treat mania in bipolar disorder, the average weight gain was 
7.05 pounds with 9% of subjects gaining more than 7% of 
their body weight.32 In 8-week studies of quetiapine in bipo-
lar disorder, average weight gain was 2.2 to 3.53 pounds.33 
Studies of asenapine in schizophrenia show lower weight 
gain profiles than other atypical antipsychotics;34 however, 
these studies are not directly comparable to bipolar disorder 
where the dose is typically double that of the schizophrenia 
trials (10 mg versus 20 mg total daily dose). Table 3 provides 
an overview of weight gain comparisons across several 
antipsychotics.
Clinical situations where asenapine  
may be the preferred agent
Asenapine was recently introduced and the clinical indica-
tions, which may distinguish it from other treatments of 
mania, are lacking. The pharmacology of asenapine offers 
a commonsense approach to guide its use. One benefit of 
asenapine for some patients is the sublingual application,   
a preferred option for patients who cannot take medica-
tions by tablet because of medical or behavioral reasons, 
for example, a patient who cannot swallow pills due to 
an esophageal stricture, gastric bypass surgery, or gen-
eral unwillingness to swallow pills. Other areas where 
sublingual medication is especially important include 
crisis intervention requiring rapid onset, or with patients 
who may be reluctant to take medication, such as an 
inpatient setting or forensic setting where patients may 
Table 3 Side effect profiles of antipsychotics in adults with bipolar disorder
FDA indication Sedation Weight  
gain
Diabetes EPS Prolactin  
elevation
QTc  
prolongation
Aripiprazole Manic/mixed episodes and maintenance − +/− − + − −
Asenapine Manic/mixed episodes ++ ++ ++ + +/− +
Chlorpromazine Mania +++ ++ ++ ++ ++ ++
Haloperidol Psychosis + + + +++ +++ +
Olanzapine Manic/mixed episode and maintenance ++ +++ +++ +/- + +
Quetiapine Manic episodes and depressive episodes  
and maintenance
++ ++ ++ − − ++
Risperidone Manic/mixed episodes + + ++ ++/+ +++ +
Ziprasidone Manic/mixed episodes + +/− − +/− +/− ++
Notes: +++, very common side effect; ++, common side effect; +, less common side effect; −, uncommon side effect.
Abbreviations: ePS, extrapyramidal symptoms; FDA, US Food and Drug Administration.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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not swallow medication but rather hold it in their mouth   
(ie, “cheek it”).
The other treatment guidance comes from asenapine’s 
pharmacological profile.35 Asenapine has relatively low his-
tamine receptor 1 (H1) affinity. Histamine receptor blockade 
is often implicated in atypical antipsychotic-induced weight 
gain and sedation, suggesting less weight gain and sedation 
liability than atypical antipsychotics with high H1 affinity 
(such as olanzapine or quetiapine). Additionally, it has lower 
affinity for dopamine receptors 1,2 (D1,2) suggesting it will 
have less extrapyramidal and hyperprolactinemia effects than 
haloperidol. These attributes should be considered with indi-
viduals who are at risk for developing metabolic syndrome 
and when other medications were stopped due to intolerable 
side effects, eg, akathisia. Another clinical situation where 
asenapine may be a good choice is with QT prolongation, 
which asenapine is less apt to produce than ziprasidone.36 
Finally, there is a growing awareness that anxiety in mood 
disorders increases the severity of the illness.37,38 While there 
are no published trials of asenapine treatment of bipolar 
disorder and anxiety, asenapine acts as an inverse agonist 
at the serotonin 1 A (5HT1A) receptor, similar to anxiolytic 
busperoine39 suggesting that patients with anxiety may benefit 
from its use.
Potential asenapine contraindications
Patients who have demonstrated nonadherence in the initial 
3 weeks of treatment due to slow medication effects may fare 
better with a faster acting medication such as olanzapine. 
For patients who have cognitive deficits interfering with 
adherence to a slightly more complex regimen than other 
atypical antipsychotics (ie, twice daily and food intake 
restrictions) asenapine may not be the preferred agent. As 
there is increased risk of metabolic syndrome for asenapine, 
consideration of comorbid medical conditions is essential, 
that is, diabetes and any indications of metabolic syndrome. 
In these cases, other antipsychotics should be considered 
first (eg, aripiprazole, ziprasidone). Other comorbid condi-
tions to carefully consider are any hepatic impairment or any 
comorbid conditions, which include medication regimens 
that may be contraindicated in asenapine administration. 
Asenapine may be less indicated for mixed states only, for 
long-term use as adjunctive therapy, or for those patients and 
clinicians who may also be looking for a medication with a 
potential antidepressant effect.
In this review we provide information on reasons for 
dropout, typical side effects to expect with asenapine, and 
discuss issues related to adherence to antipsychotics in 
  general. However, this report is limited by the current lack 
of studies examining patient preferences and issues related 
to adherence with asenapine.
Conclusion
Asenapine shows promise as an option in bipolar disorder 
manic or mixed states. The side effect profile and medica-
tion administration requirements should be considered with 
each individual where treatment is indicated. The initial 
side effects to be expected and how to manage them should 
be discussed in detail by the clinician. Patients should be 
reminded that it might take weeks to experience the full 
impact of the medication. In prescribing antipsychotics, a 
general review of barriers to adherence is recommended, 
such as discussing with each patient what might interfere 
with taking the medicine, how they will remember to take 
the medicine, and how they will manage initial side effects. 
Close follow up at initial stages of treatment to track bar-
riers to adherence is recommended. There are a range of 
side effects and laboratory measures that will need to be 
monitored in prescribing asenapine, as is the case for all 
atypical antipsychotics.
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